Candida infections in psoriatic patients on anti-IL17 therapy: a case series.

We report the occurrence of those infections in psoriatic patients receiving secukinumab 300 mg. Sixteen patients, treated with secukinumab 300 mg, for one year, and documented by mycological examinations, did not present any increase in the occurrence of Candida spp. infection, even asymptomatic. Moreover, 2 patients, after secukinumab treatment, became negative for candida detection, without any additional anti-fungal therapy. Although this case series is limited in size, our results may be reassuring on the low risk of candida infection in psoriatic patients, during secukinumab therapy. PMID: 30273067 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research